JCR Pharmaceuticals Management

Management Kriterienprüfungen 2/4

JCR Pharmaceuticals CEO ist Shin Ashida , ernannt in Jun 2005, hat eine Amtszeit von 19.42 Jahren. besitzt direkt 0.009% der Aktien des Unternehmens, im Wert von ¥7.53M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.4 Jahre bzw. 4.8 Jahre.

Wichtige Informationen

Shin Ashida

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	19.4yrs
Eigentum des Geschäftsführers	0.009%
Durchschnittliche Amtszeit des Managements	6.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.8yrs

Jüngste Management Updates

Recent updates

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

Sep 06

What JCR Pharmaceuticals Co., Ltd.'s (TSE:4552) 32% Share Price Gain Is Not Telling You

Sep 04

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

Aug 23

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Aug 09

Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts

Aug 03

JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00

Jul 26

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

Jul 12

JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

May 22

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Mar 18

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

Feb 29

Geschäftsführer

Shin Ashida (81 yo)

19.4yrs

Amtszeit

Mr. Shin Ashida has been the Chairman of JCR Pharmaceuticals Co., Ltd. since July 1995 and its Chief Executive Officer since June 2005. Mr. Ashida has been the President and Chief Operating Officer of JCR...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Shin Ashida	Chairman	19.4yrs	keine Daten	0.0085% ¥ 7.5m
Yoshihiro Ota	Director of Accounting Department & Corporate Strategy Department (Finance)	no data	keine Daten	keine Daten
Yutaka Honda	Sr. Exec. Offi. of Admin.	8.4yrs	keine Daten	keine Daten
Hiroyuki Fukuya	Director of Legal Affairs Department - Administration Division	no data	keine Daten	keine Daten
Toru Ashida	Director	4.6yrs	keine Daten	0.22% ¥ 189.9m
Ryutaro Makino	Director of Marketing Dept. & Group Manager of Product Planning - Marketing Dept. for Sales Div.	4.1yrs	keine Daten	keine Daten
Katsuya Nishino	Executive Vice President	14.3yrs	keine Daten	keine Daten
Hiroshi Yoshimoto	Senior Advisor	13.5yrs	keine Daten	keine Daten
Takayo Egawa	Senior Executive Officer & Director of International Affairs	no data	keine Daten	keine Daten
Toshihiro Ishikiriyama	Senior Managing Executive Officer & Executive Director of Business Development Division	less than a year	keine Daten	0.0066% ¥ 5.8m
Hiroyuki Sonoda	Senior Managing Executive Officer of Research	6.4yrs	keine Daten	0.0019% ¥ 1.7m
Junichi Ando	Managing Executive Officer of Production & Executive Director of Production Division	3.4yrs	keine Daten	keine Daten

6.4yrs

Durchschnittliche Betriebszugehörigkeit

70yo

Durchschnittliches Alter

Erfahrenes Management: 4552Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (6.4 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Shin Ashida	Chairman	19.4yrs	keine Daten	0.0085% ¥ 7.5m
Toru Ashida	Director	no data	keine Daten	0.22% ¥ 189.9m
Hiroyuki Sonoda	Senior Managing Executive Officer of Research	4.8yrs	keine Daten	0.0019% ¥ 1.7m
Yoshio Hiyama	Director	3.4yrs	keine Daten	0.0021% ¥ 1.9m
Andrea Spezzi	Director & Managing Executive Officer of Development Division	less than a year	keine Daten	keine Daten
Marc Dunoyer	Independent Outside Director	1.4yrs	keine Daten	keine Daten
Kazuhiko Yamada	Outside Audit & Supervisory Board Member	18.4yrs	keine Daten	0.010% ¥ 9.2m
Philippe Fauchet	Independent Outside Director	2.4yrs	keine Daten	keine Daten
Toshihide Yoda	Independent Outside Director	6.4yrs	keine Daten	keine Daten
Yutaka Atomi	Independent Outside Director	2.4yrs	keine Daten	keine Daten
Takashi Suetsuna	Independent Outside Director	7.4yrs	keine Daten	keine Daten
Yuko Hayashi	Independent Outside Director	6.4yrs	keine Daten	keine Daten

4.8yrs

Durchschnittliche Betriebszugehörigkeit

65.5yo

Durchschnittliches Alter

Erfahrener Vorstand: 4552Die Vorstandsmitglieder gelten als erfahren (4.8 Jahre durchschnittliche Amtszeit).

JCR Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

JCR Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 26, 2024

JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes

Jcr Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Appoints Yoh Ito as Senior Corporate Officer

JCR Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Appoints Pascal Yoshida as Senior Director, Head of Medical Affairs Unit

Recent updates

New minor risk - Share price stability

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

JCR Initiates First Dosing in Phase I Clinical Trial of JR-441 for Mucopolysaccharidosis Type IIIA

JCR Pharmaceuticals Co., Ltd. Announces Interim Dividend

JCR Pharmaceuticals Co., Ltd. Presents Preclinical Gene Therapy Research at the European Society of Gene and Cell Therapy 31st Annual Congress

Upcoming dividend of JP¥10.00 per share

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

What JCR Pharmaceuticals Co., Ltd.'s (TSE:4552) 32% Share Price Gain Is Not Telling You

JCR Pharmaceuticals Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Investor sentiment deteriorates as stock falls 17%

Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts

First quarter 2025 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd Announces Discontinuation of TEMCELL HS Inj. Expanded Indication Development for Neonatal Hypoxic Ischemic Encephalopathy

JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

Final dividend of JP¥10.00 announced

MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB

Consensus EPS estimates fall by 17%

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024

Price target decreased by 10% to JP¥1,314

JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Investor sentiment deteriorates as stock falls 22%

Full year 2024 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 26, 2024

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2024, Payable on June 27, 2024

Upcoming dividend of JP¥10.00 per share

JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from FTSE All-World Index (USD)

JCR Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on May 10, 2024

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes

Now 22% overvalued

JCR Pharmaceuticals Co., Ltd. Presents Clinical Data on J-Brain Cargo®? to Deliver Medicines Across the Blood-Brain Barrier

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Price target decreased by 10% to JP¥1,657

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Jan 26, 2024

New major risk - Share price stability

JCR Pharmaceuticals Co., Ltd. Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

JCR Pharmaceuticals Co., Ltd. Declares Interim Dividend for the Fiscal Year Ending March 31, 2024, Payable on December 8, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

JCR Pharmaceuticals Co., Ltd. Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)

Upcoming dividend of JP¥10.00 per share at 1.5% yield

Investor sentiment improves as stock rises 18%

PHC IVD and JCR Announce GROWJECTOR® Duo

JCR Pharmaceuticals Co., Ltd. to Report Q2, 2024 Results on Oct 25, 2023

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Consensus EPS estimates increase by 13%

First quarter 2024 earnings released: EPS: JP¥12.90 (vs JP¥11.05 in 1Q 2023)

Price target decreased by 7.4% to JP¥1,859

JCR Receives Approval to Start Global Phase I/II Clinical Trial for JR-441 for the Treatment of Mucopolysaccharidosis Type III A (MPS IIIA)

Jcr Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Receives an Approval for Expanded Indication of Growject®? in Short Stature Due to SHOX-Deficiency

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 20%

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Jul 26, 2023

Consensus EPS estimates fall by 24%

Full year 2023 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 22, 2023

Investor sentiment deteriorates as stock falls 18%

Now 21% undervalued after recent price drop

Consensus revenue estimates fall by 17%

Upcoming dividend of JP¥10.00 per share at 1.3% yield